CEL-SCI Corp. (CVM) is “One to Watch”
CEL-SCI Corp. is a biopharmaceutical company dedicated to improving the treatment of cancer and other infectious diseases by unleashing the power of the body's immune system. The company's flagship product is Multikine, the first immunotherapeutic agent being developed as a standard of care treatment for cancer. The company's Multikine has been designated as an orphan drug by the US Food and Drug Administration (FDA) and has recently begun a global Phase III trial in advanced primary head and neck cancer patients. In earlier trials, the drug was shown to kill approximately 50 percent of tumor cells before standard treatments start.…